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1. Introduction
Skin cancer shows the highest incidence worldwide, among all cancer types, and is mainly
classified in melanoma and non-melanoma subtypes.
Clinical evaluation through dermatoscopy is a widely performed practice, and it is a nonin‐
vasive technique that uses magnification to allow better visualization of the structures
immediately below the skin surface. This examination provides morphological criteria for
distinguishing various lesions types.
Histopathology is considered the gold standard for diagnosis of skin cancer and other dermal
disorders. These two exams together, as well as the location and extent of the injury will
determine the choice of treatment.
Treatments such as surgical excision, cryotherapy, topical application of imiquimod cream and
5-fluorouracil cream, and radiotherapy are commonly chosen based on the depth and exten‐
sion of the lesions. Limitations and side-effects of the conventional therapies motivate the
development of other techniques. Photodynamic therapy (PDT) is presented as an alternative
treatment for basal cell carcinoma (BCC).
PDT has proven to be effective with an excellent cosmetic outcome in the treatment of
superficial BCC (sBCC), and recently published guidelines state that PDT can be an effective
and reliable treatment option for the treatment of thin nodular BCC (nBCC), and actinic
keratosis (AK) [1]. It is a technically simple noninvasive procedure that offers patients at least
equal efficacy and a high level of satisfaction and other cosmetic outcome when compared with
cryotherapy and topical treatments [2].
© 2013 Andrade et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The term field cancerisation or field effect is frequently used to describe extensive UV damage
with recurrent, multiple AK, and the presence of a tissue with genetically altered cells is a risk
factor for cancer development, representing an indication for topical PDT [3].
Our group has extensive experience in clinical PDT in various areas of medicine as in gyne‐
cology [4], infectious disease [5], and in particular in dermatology [6-7], and in this chapter
will be discussed the advantagens and indications of the PDT for non-melanoma skin cancer
and others conditions.
2. Basic principles
Photosensitized oxidations have been of interest to chemists and biologists since Raab's
discovery that microorganisms are killed by light in the presence of oxygen and sensitizing
dyes [1].
The mechanism of action of photosensitizers is divide in two different types and generally
involves direct oxidation by hydrogen peroxide (H2O2), superoxide anion radical (O2 ∙) and
hydroxyl radical (∙OH) (Type I reaction) of biological targets (membranes, proteins, and
DNA), as well as oxidation mediated by singlet oxygen (1O2) that is mainly formed through
energy transfer from triplet states to molecular oxygen (Type II reaction) [8-10].
The generation of Reactive Oxygen Species (ROS), in both types I or II, are dependent on the
uptake of a photosensitizing dye, often a haematoporphyrin derivative, by the tumor or other
abnormal target tissue, the subsequent irradiation of the tumor with visible light of an
appropriate wavelength, and the presence of molecular oxygen [10]. An adequate concentra‐
tion of molecular oxygen is also needed for tissue damage. If any one of these components is
absent, there is no photodynamic response, and the overall effectiveness therefore requires
careful planning of both tissue photosensitization and light dosimetry.
PDT response is induced by more than one cellular mechanism. A photosensitiser can directly
target the tumor cells, inducing necrosis or apoptosis (Figure 1) [11]. Alternatively, tumor
necrosis can be induced by damaging its vasculature [12].
Figure 1. Treatment procedure for topical PDT. A) Skin cancer lesion; B) Cream application (MAL or ALA); C) Occlusion
of the lesion; D) Illumination; E) Inflammation and tecidual necrosis; F) Curative
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3. Photosensitizers
The photosensitizers are by definition any substance capable of making an organism, a cell or
a substance photosensitive, with the photo-excitation of several types of molecules through
energy transfer processes. Porphyrins, chlorines, phthalocyanines are the three main groups
of studied photosensitizers (PSs). Porphyrins are the most frequently used PSs, but its systemic
administration shows an important adverse factor in Dermatology. Due to the high accumu‐
lation and slow drug clearance from the skin, porphyrins lead to prolonged photosensitization
of the organism after application [13]. The commercially available compounds promote a
patient photosensitization that lasts for 4-6 weeks. These PDT patients must avoid sun
exposure during this period, otherwise skin burns can be induced. This is the major drawback
for indication of PDT in Dermatology.
The development of an ideal PDT sensitizer is still a major challenge since several character‐
istics must be contemplated. Main characteristics are: a) photo-excitation with red-infrared
light; b) low dark toxicity; c) high stability; d) rapid clearance from the body; e) high affinity
to abnormal cells (selectivity), and f) high rate of ROS production.
The main reactions observed with biological molecules are lipid peroxidation (cholesterol),
cycloaddition (2 +2)-protein (reaction with tryptophan) and Diels-Alder reactions upon
molecules in the genetic code (guanine). Porphyrin derivatives are indeed intersting molecules.
Compounds such as porphyrins and chlorins, have the characteristics suitable for use in PDT
due to the high molar extinction coefficients, high absorptivities in the region of the "thera‐
peutic window" (600-800 nm) and with high quantum yields of singlet oxygen production.
PDT can also be performed with topical use of 5-aminolevulinic acid (5-ALA) or by its ester
methyl-aminolevulinate (MAL), which are both precursors in the biosynthesis of protopor‐
phyrin IX (PpIX), a native photosensitizing compound that accumulates in the cells. Proto‐
porphyrin IX (PpIX) has absorption peaks at 505, 540, 580 and 630 nm.
These compounds must be stored in the form of hydrochloride (R-NH3Cl), since in its neutral
form rapidly suffers degradation. Studies including a few with 5-year follow-up, have shown
that ALA and MAL-PDT are comparable to other modalities in the treatment of superficial
lesions considering their efficacy and with equivalent or superior cosmetic outcomes [14-15].
ALA and MAL are not photosensitizers, they are precursors of endogenous PpIX (Figure 2).
Figure 2. Molecular structures of the PpIX precursors.
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The fundamental difference between ALA and its methyl ester (MAL) is the more hydrophobic
character of the MAL. Thus, MAL can better penetrate through the cell membranes and more
easily reaches the deepest epidermal layers. However, the biosynthesis of protoporphyrin IX
production from MAL is slightly more time consuming because of the need of hydrolysis of
this compound.
Chlorin is a photosensitizer indicated in the cases of PDT using i.v. medication. It is derived from
natural or synthetic tetrapyrroles, and an important feature is their strong light absorption in the
spectral region usually above 660 nm. A significant advantage of PDT using chorins is the reduced
duration of cutaneous photosensitivity as compared with other photosensitizers [16].
Recently, eight new chlorins with amphiphilic properties were synthesized from PpIX.
Biological studies of some of these new chlorins indicate the great potential of these com‐
pounds as photosensitizers in PDT [17].
4. Dosimetry
Distinct light sources can be used for PDT. For therapy, the tissue must be irradiated with light
at appropriate wavelengths (within the absorption spectrum of porphyrins). The porphyrins
exhibit a very typical absorption spectrum with the highest peak at approximately 405 nm,
called the Soret-band. Other lower absorption peaks, the Q-bands, are centered at 510, 545, 580
and 630 nm. The absorption band at 630 nm is preferentially used for irradiation since light at
the red spectrum results in a higher skin penetration. Lasers and incoherent light sources
(lamps, light-emitting-diode – LED – lamps and, intense pulsed light – IPL) have been used.
When endoscopic applications are necessary, the activating light has to be delivered through
optical fibers, and laser systems are the best option for this purpose. For dermatological
application, incoherent light sources are more attractive, due to the possibility of distinct
emission geometries and comparable lower cost [18-20].
The therapeutic efficacy of PDT involves administration to the patient of a photosensitizer or
a pro-drug, a waiting time to allow adequate concentration of the sensitizer molecules in the
tumor, and irradiation of the target tissue with a proper wavelength to activate the photosen‐
sitizer generating cytotoxic products, mainly the singlet-oxygen. To trigger cell death, a
minimum number of singlet-oxygen molecules have to be produced. The minimal energy dose
required to achieve the irreversible tissue damage, resulting in tumor necrosis, is called the
threshold dose.
The energy dose is given in Joules per centimeter square (J/cm2), that is the amount of energy
delivered to the tissue per unit area. Light intensity is measured in Watts (W) and corresponds
to the energy per unit of time. One W corresponds to 1 J per 1 second. Irradiance is measured
in Watts per centimeter square (W/cm2), representing the light power delivered to the tissue
surface [19, 21-22]. A simple relationship between light dose (D), irradiance (I) and time (t) is:
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D=I.t (1)
Energy doses delivered for the treatment of basal cell carcinoma and other dermal conditions
are in the range of 40-150 J/cm2 and with irradiances of 40-150 mW/cm2. The PDT illumination
of a BCC lesion of 2 cm of diameter, for example, may be of 8 to 20 minutes, depending on the
chosen irradiation parameters.
5. Clinical results
Nonmelanoma skin cancer is the most frequent one in the world population. Currently,
therapeutic options are surgical ressection, electrocoagulation, curettage, cryotherapy,
immunomodulating agents, cytotoxic agents, chemotherapy, PDT, among others. PDT is a
noninvasive technique with excellent cosmetic outcome, well tolerated by patients and with
good healing results, when used for the initial stages of cancer lesions. Different studies show
the technique effectiveness for BCC (Figure 3 and 4), presenting curative rates ranging from
52.2% to 100% [7, 23-28].
Figure 3. Nodular BCC before (A) and 30 days after (B) PDT, treated with MAL 20% in 2 sessions and dose of 100J/cm2
Figure 4. Superficial BCC before (A) and 30 days after (B) PDT, treated with MAL 20% in 2 sessions and dose of
100J/cm2
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Wolf et al., (1993), in their study treated 70 different lesions – superficial BCC, actinic keratosis
(AK), nodular-ulcerative BCC, squamous cell carcinoma (SCC) and melanoma – using ALA
cream, with dose of 30J/cm² for superficial BCC and AK and 100 J/cm²-300 J/cm² for other
lesions. Results at 12 months showed complete response for AK, 36 of 37 superficial BCC
lesions showed good responses, 5 of 6 SCC, 8 cutaneous metastases of malignant melanoma
were therapeutic failures and other lesions showed a partial response after treatment [23]. In
the study by Calzavara (1994), which also included several lesions (AK, BCC, nodular BCC,
pigmented BCC and SCC), all treated with ALA 20%, there were complete response in 100%
for BCC and AK cases, decreasing to 80% in nodular lesions. Other treated lesions exhibited
low curative rate when evaluated 30 days after treatment. These curative rates decreased to
86.9% in BCC and 50% in nodular BCC in the clinical follow-up done for 29 months [27].
According to the study of Souza et al., (2009), after evaluating 20 patients (showing difficulties,
impediment high risk or rejection of surgical procedure) with BCC and Bowen's disease (BD)
treated with ALA 20%, irradiated at wavelength of 630 nm and doses of 100 to 300 J\cm²,
showed that, after 1 session, presented curative rates of 91.2% at three months and 57.7% at
sixty months [7].
Horn et al., (2003), treated 94 patients with 108 superficial, nodular and mixed BCC lesion with
difficult to treatment (resulting scars from reconstructive surgery extensive, interfering with
normal function of eyelids or lips, or postoperative infections), finding complete response after
3 months in 92% of superficial BCC and 87% of nodular BCC. The cosmetic outcome was
evaluated as excellent or good by investigators in 76% of the lesion after 3 months follow-up,
increasing to 85% at 12 months and 94% at 24 months follow-up [29].
A recent study comparing CO2 laser ablation versus PDT in immunocompetent patients with
multiple AK concluded that both treatments were effective in reduction of AK, but PDT seems
to be superior in terms of reduction of the affected area and overall satisfaction by patients and
clinicians [30].
Foley et al., (2009), conducted a double-blind and placebo-controlled study in primary lesion
of nodular BCC (up to 5 mm in depth) in two medical centers. MAL was used at concentration
of 160 mg/g cream or placebo cream, with three hours of occlusion. The light source applied
was in the range of 570-670 nm, with an irradiance of 50-200 mW/cm² and dose of 75 J/cm². In
total, 131 patients with 150 lesions were included in the study, 66 patients with 75 lesions were
treated with MAL cream and 65 patients with 75 lesions with placebo cream. The treatment
was developed in cycles. The first cycle was conducted in two sessions, with one week interval
between sessions. If the response was partial (≤50% reduction in greatest diameter) after 3
months follow-up, the second cycle was initiated with two more sessions with one week
interval, and monitoring the patient for six months. If the answer was not complete, the
responsible medical team indicated the patient for surgical procedure. The complete response
after 6 months follow-up, with MAL was of 73% (55/75 lesions) versus 27% (20/75 lesions) with
placebo. The response decreases in larger lesion (≥ 10mm in diameter and ≥ 1mm of baseline
depth). The cosmetic outcome of the lesions treated with MAL-PDT was good or excellent in
98% of the cases [24].
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Caekelberg et al., (2009), observed the PDT result after 6 months in 90 patients with superficial
BCC of approximately diameter 10 mm. The complete response rate was of 88.1% with cosmetic
outcome qualified as excellent in 96.25% of patients [25].
Interesting results were achieved in the study of Surrenti et al., (2008), where they evaluated
the PDT response in nodular and superficial BCC. In this study, 118 lesions were treated in 69
patients, located at the chest, face, head, neck and limbs. Superficial BCC were diagnosed in
94 lesions and 24 showed nodular BCC lesions, confirmed by histology. Complete response
was obtained in 84/94 (89.4%) at superficial BCC, and in 12/23 (52.2%) at nodular BCC, when
evaluated at 30 days after the second session. The cosmetic outcome was evaluated as excellent
in 83% of cases and good in the remaining 17% of the cases [28].
Szeimies et al., (2008), compared PDT with surgery to treat superficial BCC between 8-20 mm
size, in 196 patients with 234 lesions. The lesions treated with MAL 160 mg/g, in two sessions,
showed a curative rate of 92.2% compared to 99.2% of the lesions treated with surgery, when
assessed after 3 months of treatment. After 12 months, the cosmetic outcome was considered
by the investigator as good or excellent in 92.8% of patients treated with PDT versus 51.2% of
patients treated with surgery. The recurrence was 9.3% in comparison with 0% for lesions
treated with PDT and surgery, respectively [26]. In nodular BCC treatment curative rates, after
three months, of 91% with PDT versus 98% with surgery were obtained. After 12 months, 96%
of lesions treated with surgery showed complete response compared to the 83% of the lesions
treated with PDT. This study was performed on 97 patients with 105 lesions, all confirmed by
histopathology [31].
In a recent study, (2012), was compared PDT with surgery, in 72 patients with 94 lesions
superficial and nodular BCC with a maximum 3 mm thick. The patients were separated into
two groups according to their choice of treatment, being 48 lesions treated with PDT and 46
with surgery. After 3 months, the curative rate was 95.83 % with PDT versus 95.65% with
surgery. The recurrence rate was, after 12 months, 4.16% for PDT compared to 4.34% for
surgery [32].
Basset-Seguin et al., (2008) presented results comparing PDT with cryotherapy in 118 patients.
The authors used PDT protocol with MAL and two sessions separated by 7 days. The complete
clinical response, after 3 months of treatment, was of 97% with cryotherapy versus 95% with
PDT. Comparing the cosmetic outcome, they obtained excellent and good response in 54%
versus 93% with cryotherapy and PDT, respectively [33].
Another multicenter study made by Aguilar et al., (2010), compared imiquimod and PDT with
surgery in the treatment of 54 Bowen's disease lesions (63%) and 32 superficial BCC lesions (37%).
After 24 months, the curative rate was of 97.5% for surgery, 89.5% for PDT, and 87.5% for
imiquimod. The surgery cost was approximately twice the value when compared to PDT [34].
The differences between the curative results obtained in the different studies is mainly due to
the distinct treament protocols: a) different lesion selection criteria (diameter, length, thickness,
site, previous treatment); b) no standardization of the pre-PDT procedures (shaving, curettage,
scarification); c) distinct drugs (ALA, MAL); d) different cream incubation times (2, 3 and 4
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hours); e) distinct irradiation parameters; f) number of sessions; g) different treatment
evaluation times (1, 3 or 6 months) and time to evaluate recurrence (6 months, 1, 3, 5 or 10
years) [35]. However, thicker lesions and nodular BCC present lower curative rates when
compared to superficial BCC [26, 28, 33, 35]. Furthermore, pretreatment procedures as shaving
or curettage [29], and multiple sessions [15, 36] can increase positive response to PDT [35].
PDT may present some adverse reactions such as photosensitivity, infection, erythema, edema,
pain, among others [24, 37]. In topical PDT, the photosensitive drug is localized in lesion and
consumed after irradiation. Reports of local photosensitivity after treatment are scarce, and
when present, are present in the following 24 hours after irradiation. The systemic PDT, on
the other hand, has a longer photosensitivity time [23]. Infection is a complication that almost
does not occur due to the proven action of PDT for microbiological control [37]. However,
some factors may predispose to this occurrence, such as, diabetes, peripheral vascular disease,
and others. In a study by Wolfe et al., (2007), 700 AK lesions were treated with PDT and only
4 cases of cellulitis were reported, but easily controled by antibiotic therapy [38]. Changes in
pigmentation, hyper and hypopigmentations, are reported in literature as approximately 1%
of all adverse reactions [37]. The pain may be present during irradiation or within 7 days after
treatment. In the study by Morton et al., (2001), only one third of patients treated had pain
qualified between moderate and severe [39]. In the experiment by Ibbotson et al., (2011), during
9 years, different lesions were trated with topical PDT, 16% of patients showed severe pain
and 50% moderate pain [37]. In a multicenter, randomized, controlled and open study,
comparing PDT with surgery it was found that for PDT, 37/100 (37%) of patients had an adverse
reaction versus 14/96 (14,6%) of patients treated with surgery. For PDT, photosensitivity
reaction, which includes sensations of discomfort, burning and erythema was the most
frequent, these reactions were of mild to moderate intensity and easily treated. For surgery,
the more expected reaction was infection, that occured in 5 of the 14 patients and requiring the
use of systemic antibiotics for two weeks [26].
PDT can be associated with other treatment techniques, such as surgery, as described by Willey
et al., (2009). In this study, surgical ressection was associated with PDT with 20% ALA for
recurrence prevention. The PDT protocol consisted of an hour of inoculation and illumination
with a light source with wavelength at 417 nm during 1000 seconds (irradiance of 10 mW/cm²).
The PDT cycles were repeated every 1-2 months for two years. In the first year after first PDT
session, average reduction of lesions appearance was around 80%, reaching values of 95%
reduction by the end of the second year [40].
The recurrence of BCC lesions when treated with traditional techniques has been estimated of
36% after one year of treatment, 61% after two years and 18% after 6 to 10 years of treatment
[41]. For PDT, several studies have been published assessing the lesion recurrence after 1 to 5
[7, 15, 33, 42-43], 6 and 10 years of treatment [44].
In the clinical study done by Souza et al., (2009), the treated patients were monitored (or
followed) for 60 months. The lesion recurrence was presented in 11/26 lesions (42.3%), the
recurrence depending on the lesion types were of 2/5 for nodular BCC, 2/6 for superficial BCC
and 7/15 to Bowen's disease [7].
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According to Basset-Seguin et al., (2008), recurrence after 5 years of PDT in 103 superficial BCC,
using MAL, was of 22%, all present in the first three years after treatment. This rate is compa‐
rable with the one obtained in patients treated with cryotherapy [33]. In the study by Mosterd
et al., (2008), 83 nodular BCC were treated with 20% ALA-PDT and fractionated irradiation
with a total dose of 150J/cm². A recurrence rate of 30.3% were obatined after 3 years. In this
study, the thicknesses of 78 lesions were measured and an increased failure risk was present
in thicker lesions, over 1.3 mm (42.2%), when compared to the thinner ones (15,5%) [42]. In a
study by Rhodes et al., (2004), 53 nodular BCC, treated with MAL-PDT, a recurrence rate of
14% was observed after 5 years of treatment. A recurrence in 5/40 lesions treated with one PDT
session and 2/9 treated with two PDT sessions, occuring especially in the first two years of
treatment. When compared with surgery, the recurrence rate decreases to 4% [31]. Similar
results were reported in a study of Szeimies et al., (2008), with recurrence rates for PDT of 9.3%
and 0% for surgery, in a follow-up of 12 months [24].
Another study evaluating 157 BCC lesions (111 superficial BCC, 40 nodular BCC and 6
histology missing) in 90 patients treated with two sessions of MAL-PDT, recurrence rates
estimated of 7% in the first 3 months, 19% in 6 months, 27% in 12 months and 31% in 24 months
after treatment were obtained. When comparing recurrence rates at 12 months of nodular and
superficial BCC the rates were of 28% versus 13%, respectively [43].
Christensen et al, (2009), classified 60 BCC (24 nodular BCC e 36 superficial BCC), according to
size, as smaller than 1 cm, between 1-2 cm and larger than 2 cm. All lesions were curetted and
DMSO was applied at the site for 5 min, then 20% ALA cream was applied and kept in position
for 3 hours. PDT procedure was performed in one or two sessions. After 6 years follow up, 43/53
(81%) of lesions still showed complete response. Five patients were excluded for presenting partial
response to treatment in the first three months and two patients died at the onset of follow-up
period from causes unrelated to study. The recurrences were present before three years, with two
thirds of these presented in the first 12 months. The average age of the patients with recurrence
was of 76 y.o. for men and 77 for women. Considering lesion size, no statistical difference was
observed because only one lesion measured more than 2 cm [45]. The follow up of 10 years, showed
an overall curative rate of 75%, 60% for lesions treated with one session and 81% for two ses‐
sions, all recurrence cases were presented in the first three years [44].
Multiple factors have been associated with recurrence in the different studies. Few sessions
are associated with high recurrence rates. One PDT session is the major factor for treatment
failure [33, 44, 46]. In the study by Soler et al., (2001), 33 lesions presented recurrence, 29 of
them treated with a single session and four treated with two sessions [46]. Similar data were
found by Christensen et.al., (2009), where 43/53 lesions remained disease-free; 68% after one
treatment session and 91% after two treatment session [45].
Size and thickness are factors that also affect lesion recurrence. The study by Mosterd et al.,
(2008), presented recurrence rates of 42% in the lesions with ≥ 1,3 mm thickness, and of 15.5%
for lesions ≤ 1,3 mm. Horn et al., (2003), showed an increased recurrence associated with lesion
size when evaluated 24 months after treatment. Lesions of 0-15 mm presented 4% recurrence,
increasing to 16% in lesions of 16-30mm and greater than 30mm, 33% [29].
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Author and type of
study Treatment Procedure Study size Result
Soler et al., (2001)
Retrospective study [46]
MAL 160 mg/g
Preparation prior PDT:
Debulking procedure was performed
on all nodular.
Total: 310 lesion
131 sBCC
82 nBCC ≤ 2mm thickness
86 nBCC ≥2mm thickness
3 mo, Complete Response
91% sBCC
93% nBCC thin
86% nBCC thick
11% Recurrence at 35 mo
Horn et al., (2003)
Open-label study [29]
MAL 160 mg/g cream
Pre-PDT procedure in nodular lesions:
Shaving.
Total:108 lesions
49 sBCC
52 nBCC
7 mixed BCC
3 mo, Complete Response
92% sBCC
87% nBCC
57% mixed BCC
9% Recurrence at 12 mo
18% Recurrence at 24 mo
Basset –Seguin et al., (2008)
Randomized, comparative,
multicenter study [33]
MAL cream
Preparation pre-PDT:
Surface debridement
Total 201 lesions
103 sBCC with PDT
98 sBCC with cryotherapy
3 mo, Complete response
97% PDT
95% Cryotherapy
Recurrence at 5 years
22% PDT
20% Cryotherapy
Szeimies et al., (2008)
multicentre, randomised,
controlled, open study [26]
MAL 160 mg/g cream
Preparation pre-PDT:
remove scales and crust of lesion
surface
Total 196 lesions
100 sBCC with PDT
96 sBCC with surgery.
3 mo Complete response
92.2% PDT
99.2% Surgery
Recurrence at 12 mo
9.3% PDT
0% Surgery
Christensen et al., (2009) and
(2012)
Prospective study study
[44-45]
ALA 20%
DMSO 99%
Preparation pre-PDT: curettage
Total:60 lesion
24 sBCC
36 nBCC
3 mo, Complete response
92% total lesion
72 mo, Complete response
81% total lesion
120mo, Complete response
75% total lesion
Lindberg-Larsen et al., (2012)
Retrospective study [43]
MAL 160 mg/g
Preparation pre-PDT:
Superficial lesions were debrided.
Nodular lesions were curetted
Total: 157 lesion
111 sBCC
40 nBCC
6 unknown
3 mo Complete response
93% lesion
Recurrence at 12 mo:
nBCC 28%
sBCC 13%
Cosgarea et al., (2012)
prospective, comparative,
controlled, clinical study [32]
ALA 20% cream
Preparation pre-PDT: remove scales
and crusts of lesion surface
Total 94 sBCC
48 lesions with PDT
46 lesions with Surgery
3 mo Complete response
95.83% PDT
95.65% Surgery
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Author and type of
study Treatment Procedure Study size Result
Recurrence at 12 mo
4.16% PDT
4.34% Surgery
Table 1. Study results of topical PDT for non melanoma skin cancer
A higher recurrence rate is also present at nodular BCC, when compared to the superficial BCC
[43, 46]. Age can be a factor that increases the lesion recurrence treated with PDT, other
potential factors are gender and lesion site [43].
6. Non-oncological and off-label pdt applications in dermatology
PDT is already approved for the treatment of actinic keratosis and basal cell carcinoma. Off-
label uses for PDT have been indicated for several dermatological conditions such as photo-
damaged  skin,  scleroderma,  warts,  cutaneous  leishmaniosis,  psoriasis,  cutaneous  T-cell
lymphoma and acne [20, 47]. Infectious disease has the potential to become one of the main
indications of PDT in Dermatology. The microbiological control of bacteria, fungi and protozoa
in infected lesions has been presented [48-51]. Onychomicosis is one of the new indications, where
PDT presents good results even in cases where the antifungal systemic therapy failured (Paula-
da-Silva, A. et al., Fast elimination of onychomycosis by hematoporphyrin derivative-photody‐
namic therapy. Accepted by Photodiagnosis and Photodynamic Therapy on December2012).
7. Final considerations
PDT is a noninvasive technique, with few potential adverse reactions, that presents good
curative rates and excellent cosmetic outcome. It may be chosen as a first option for patients
with small lesions of nonmelanoma skin cancer, especially the ones in complex sites for surgical
ressection or in high risk patients.
PDT protocols and customized dosimetry for each target skin lesion still need to be defined.
The development of new PDT drugs and delivery systems has the potential of increasing the
curative rates of the present protocols. Instrumentation of light sources designed to adapt the
emission geometry to the anatomical site characteristics is also important to improve PDT
performance in cancer treatment.
The local treatment of infected lesions and cosmetics are PDT indications that have been fastly
increasing. New protocols and drugs have been investigated, as well as new light devices
developed, making PDT in Dermatology an exciting and growing field.
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